慢性胃病幽门螺杆菌初治及补救治疗疗效分析  

Effect of Lizhuweisanlian combined with Killing Hp Capsules on 126 patients with chronic gastritis

作　　者：姚洪森[1] 姚冬梅[2] 张健[1] 姚希贤[2] 赵丽梅[2] 刘艳 

机构地区：[1]武警河北总队机关门诊部,石家庄050051 [2]河北医科大学第二医院消化内科,石家庄050000 [3]武警河北总队卫生处,石家庄050051

出　　处：《武警医学》2012年第2期133-135,138,共4页Medical Journal of the Chinese People's Armed Police Force

摘　　要：目的探讨丽珠维三联联用"灭Hp胶囊"对慢性胃病Hp根除疗效及"PPI三联序贯"方案联用"灭Hp胶囊"对根除Hp失败者补救治疗疗效。方法初治者139例,分为治疗组(A组)和对照组(B组),A组:联用"灭Hp胶囊",共7 d;B组:丽珠维三联,共7 d;复治者121例,分为治疗组(补A组包括补A1、A2、A3)和对照组(补B组),观察各组疗效。结果初治者Hp根除率A组90.60%,B组83.33%,差异无统计学意义(P>0.05);不良反应发生率A组低于B组(2.08%vs 10%)。抗-Hp补救治疗者Hp根除率补A1组63.33%,补B组60.00%,差异无统计学意义(P>0.05);补A2、A3组疗效达80%以上,不良反应发生率补A组明显低于补B组(P<0.01)。结论丽珠维三联尤其"PPI三联序贯"方案与"灭Hp胶囊"联用有良好的协同作用,可提高铋剂或PPI三联的抗Hp疗效,减少不良反应发生率。Objective To study the effect of lizhuweisanlian combined with Killing Hp capsules on patients with chronic gastropathy and the effect of remedy treatment with PPI triple therapy and Killing Hp capsules on refractory patients.Methods 139 patients under initial treatment were divided into two groups at random.The study group（A） was given lizhuweisanlian and Killing Hp capsules for seven days while the control group（B） was given lizhuweisanlian for seven days.121 patients for retreatment were divided into treatment group（group of supplement A,including A1,A2 and A3） and control group（group of supplement B）.Group of supplement A1 was given Lizhuweisanlian and Killing Hp capsules for 14 days,group of supplement A2 was given PPI triple sequential therapy plus Killing Hp capsules,and group of supplement A3 was given PPI triple therapy for 10 days.Results The eradication rate of helicobacter pylori in initial treatment group was 90.60% in group A and 83.33% in group B,P0.05.The total incidence rate of adverse effects including nausea,poor appetite,abdominal discomfort and skin rash was lower in group A than in group B（2.08% vs 10%）,P0.05.In remedy treatment patients,the eradication rate of helicobacter pylori was 63.33% in group A1 and 60.00% in group B,P0.05.The effective rate in A2 and A3 was over 80%,group A2（P0.01）,group A3（P0.05）.As for such adverse effects as nausea,poor appetite and abdominal discomfort,there was significant difference between group A and group B（3.33% vs 20.00%）,P0.05.The total incidence rate of adverse effects was lower in group A1 than in group B（6.67% vs 43.33%）,P0.01.Conclusions Lizhuweisanlian,especially PPI triple therapeutic scheme combined with Killing Hp capsules,has good synergism and can increase the effect of killing Helicobacter pylori while reducing adverse effects.

关 键 词：丽珠维三联 灭Hp胶囊 幽门螺杆菌 补救治疗 序贯治疗 

分 类 号：R573.1[医药卫生—消化系统]